Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers
Clinical trial NCT03860207 · TERMINATED
Trial details
- NCT number
- NCT03860207
- Sponsor
- Y-mAbs Therapeutics
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-02-22
- Primary completion
- 2021-10-20
- Enrollment
- 12
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.